Pharmamarketeer
onderzoek

Boehringer Ingelheim’s phase III INBUILD trial of nintedanib in patients across a range of progressive fibrosing interstitial lung diseases meets primary endpoint

7 oktober 2019
Pharma Biz

Boehringer Ingelheim, a research─driven pharmaceutical company, announced that in the phase III INBUILD trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)